S&P 500   2,954.22 (-0.82%)
DOW   25,409.36 (-1.39%)
QQQ   205.80 (+0.08%)
AAPL   273.36 (-0.06%)
FB   192.47 (+1.43%)
MSFT   162.01 (+2.42%)
GOOGL   1,339.25 (+1.85%)
AMZN   1,883.75 (-0.03%)
CGC   18.78 (+1.84%)
NVDA   270.07 (+6.92%)
BABA   208.00 (+1.45%)
MU   52.56 (+3.91%)
GE   10.88 (+4.72%)
TSLA   667.99 (-1.62%)
AMD   45.48 (+3.34%)
T   35.22 (-1.43%)
ACB   1.34 (-7.59%)
F   6.96 (-0.14%)
NFLX   369.03 (-0.72%)
PRI   111.34 (-3.00%)
BAC   28.50 (-2.16%)
GILD   69.36 (-4.54%)
DIS   117.65 (-0.33%)
S&P 500   2,954.22 (-0.82%)
DOW   25,409.36 (-1.39%)
QQQ   205.80 (+0.08%)
AAPL   273.36 (-0.06%)
FB   192.47 (+1.43%)
MSFT   162.01 (+2.42%)
GOOGL   1,339.25 (+1.85%)
AMZN   1,883.75 (-0.03%)
CGC   18.78 (+1.84%)
NVDA   270.07 (+6.92%)
BABA   208.00 (+1.45%)
MU   52.56 (+3.91%)
GE   10.88 (+4.72%)
TSLA   667.99 (-1.62%)
AMD   45.48 (+3.34%)
T   35.22 (-1.43%)
ACB   1.34 (-7.59%)
F   6.96 (-0.14%)
NFLX   369.03 (-0.72%)
PRI   111.34 (-3.00%)
BAC   28.50 (-2.16%)
GILD   69.36 (-4.54%)
DIS   117.65 (-0.33%)
S&P 500   2,954.22 (-0.82%)
DOW   25,409.36 (-1.39%)
QQQ   205.80 (+0.08%)
AAPL   273.36 (-0.06%)
FB   192.47 (+1.43%)
MSFT   162.01 (+2.42%)
GOOGL   1,339.25 (+1.85%)
AMZN   1,883.75 (-0.03%)
CGC   18.78 (+1.84%)
NVDA   270.07 (+6.92%)
BABA   208.00 (+1.45%)
MU   52.56 (+3.91%)
GE   10.88 (+4.72%)
TSLA   667.99 (-1.62%)
AMD   45.48 (+3.34%)
T   35.22 (-1.43%)
ACB   1.34 (-7.59%)
F   6.96 (-0.14%)
NFLX   369.03 (-0.72%)
PRI   111.34 (-3.00%)
BAC   28.50 (-2.16%)
GILD   69.36 (-4.54%)
DIS   117.65 (-0.33%)
S&P 500   2,954.22 (-0.82%)
DOW   25,409.36 (-1.39%)
QQQ   205.80 (+0.08%)
AAPL   273.36 (-0.06%)
FB   192.47 (+1.43%)
MSFT   162.01 (+2.42%)
GOOGL   1,339.25 (+1.85%)
AMZN   1,883.75 (-0.03%)
CGC   18.78 (+1.84%)
NVDA   270.07 (+6.92%)
BABA   208.00 (+1.45%)
MU   52.56 (+3.91%)
GE   10.88 (+4.72%)
TSLA   667.99 (-1.62%)
AMD   45.48 (+3.34%)
T   35.22 (-1.43%)
ACB   1.34 (-7.59%)
F   6.96 (-0.14%)
NFLX   369.03 (-0.72%)
PRI   111.34 (-3.00%)
BAC   28.50 (-2.16%)
GILD   69.36 (-4.54%)
DIS   117.65 (-0.33%)
Log in

NASDAQ:INCY - Incyte Stock Price, Forecast & News

$75.41
-0.43 (-0.57 %)
(As of 02/28/2020 04:00 PM ET)
Today's Range
$73.50
Now: $75.41
$76.44
50-Day Range
$72.95
MA: $77.38
$82.77
52-Week Range
$71.84
Now: $75.41
$96.79
Volume2.52 million shs
Average Volume1.66 million shs
Market Capitalization$16.35 billion
P/E Ratio36.79
Dividend YieldN/A
Beta1.06
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Read More…

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:INCY
CUSIP45337C10
Phone302-498-6700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.16 billion
Cash Flow$2.42 per share
Book Value$11.99 per share

Profitability

Net Income$446.91 million

Miscellaneous

Employees1,456
Market Cap$16.35 billion
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive INCY News and Ratings via Email

Sign-up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter.


Incyte (NASDAQ:INCY) Frequently Asked Questions

What is Incyte's stock symbol?

Incyte trades on the NASDAQ under the ticker symbol "INCY."

How were Incyte's earnings last quarter?

Incyte Co. (NASDAQ:INCY) announced its quarterly earnings results on Thursday, February, 13th. The biopharmaceutical company reported $0.65 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.57 by $0.08. The biopharmaceutical company had revenue of $579.40 million for the quarter, compared to the consensus estimate of $558.13 million. Incyte had a net margin of 20.70% and a return on equity of 20.05%. Incyte's revenue for the quarter was up 9.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.40 EPS. View Incyte's Earnings History.

When is Incyte's next earnings date?

Incyte is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Incyte.

What price target have analysts set for INCY?

21 brokerages have issued 1 year target prices for Incyte's shares. Their forecasts range from $74.00 to $121.00. On average, they expect Incyte's stock price to reach $91.26 in the next twelve months. This suggests a possible upside of 21.0% from the stock's current price. View Analyst Price Targets for Incyte.

What is the consensus analysts' recommendation for Incyte?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 11 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Incyte.

Has Incyte been receiving favorable news coverage?

Press coverage about INCY stock has been trending positive on Friday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Incyte earned a news impact score of 3.0 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Incyte.

Are investors shorting Incyte?

Incyte saw a decline in short interest in February. As of February 14th, there was short interest totalling 3,980,000 shares, a decline of 12.1% from the January 30th total of 4,530,000 shares. Based on an average daily trading volume, of 1,450,000 shares, the days-to-cover ratio is presently 2.7 days. Approximately 1.9% of the shares of the company are sold short. View Incyte's Current Options Chain.

Who are some of Incyte's key competitors?

What other stocks do shareholders of Incyte own?

Who are Incyte's key executives?

Incyte's management team includes the folowing people:
  • Mr. Hervé Hoppenot, Chairman, Pres & CEO (Age 59)
  • Ms. Maria E. Pasquale, Exec. VP & Gen. Counsel
  • Dr. Wenqing Yao, Exec. VP & Head of Discovery Chemistry (Age 56)
  • Dr. Steven H. Stein, Exec. VP & Chief Medical Officer (Age 52)
  • Ms. Christiana Stamoulis, Exec. VP & CFO (Age 48)

Who are Incyte's major shareholders?

Incyte's stock is owned by many different of retail and institutional investors. Top institutional investors include Capital International Investors (4.38%), State Street Corp (3.84%), Renaissance Technologies LLC (1.67%), UBS Asset Management Americas Inc. (1.50%), Geode Capital Management LLC (1.36%) and Pictet Asset Management Ltd. (0.88%). Company insiders that own Incyte stock include Barry P Flannelly, Herve Hoppenot, Jean Jacques Bienaime, Paul A Friedman, Paul Trower, Paula J Swain, Steven H Stein, Vijay K Iyengar, Wendy L Dixon and Yao Wenqing. View Institutional Ownership Trends for Incyte.

Which major investors are selling Incyte stock?

INCY stock was sold by a variety of institutional investors in the last quarter, including UBS Asset Management Americas Inc., First Trust Advisors LP, Janus Henderson Group PLC, Panagora Asset Management Inc., Massachusetts Financial Services Co. MA, Raymond James Financial Services Advisors Inc., Amundi Pioneer Asset Management Inc. and Bank of New York Mellon Corp. Company insiders that have sold Incyte company stock in the last year include Barry P Flannelly, Jean Jacques Bienaime, Paul A Friedman, Paul Trower, Paula J Swain, Steven H Stein, Wendy L Dixon and Yao Wenqing. View Insider Buying and Selling for Incyte.

Which major investors are buying Incyte stock?

INCY stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Man Group plc, Los Angeles Capital Management & Equity Research Inc., Capital International Investors, AXA, Jacobs Levy Equity Management Inc., Credit Suisse AG and Teacher Retirement System of Texas. Company insiders that have bought Incyte stock in the last two years include Herve Hoppenot and Jean Jacques Bienaime. View Insider Buying and Selling for Incyte.

How do I buy shares of Incyte?

Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Incyte's stock price today?

One share of INCY stock can currently be purchased for approximately $75.41.

How big of a company is Incyte?

Incyte has a market capitalization of $16.35 billion and generates $2.16 billion in revenue each year. The biopharmaceutical company earns $446.91 million in net income (profit) each year or $2.23 on an earnings per share basis. Incyte employs 1,456 workers across the globe.View Additional Information About Incyte.

What is Incyte's official website?

The official website for Incyte is http://www.incyte.com/.

How can I contact Incyte?

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at 302-498-6700 or via email at [email protected]


MarketBeat Community Rating for Incyte (NASDAQ INCY)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  1,113 (Vote Outperform)
Underperform Votes:  676 (Vote Underperform)
Total Votes:  1,789
MarketBeat's community ratings are surveys of what our community members think about Incyte and other stocks. Vote "Outperform" if you believe INCY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INCY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Featured Article: What is a death cross?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel